EOC Pharma, an oncology specialty biopharmaceutical company in China, and Chime Biologics, a contract development and manufacturing organization (CDMO), have extended their partnership on the CMC development of EOC202, a recombinant LAG-3 protein for cancer immunotherapy. The extended partnership will enable Chime’s world-class biologics development and manufacturing capability and capacity to become part of EOC’s engine to fuel the EOC202’s clinical development and potential c...